• Save
Angina crónica estable - Dr. José Luis López Sendón
Upcoming SlideShare
Loading in...5
×
 

Angina crónica estable - Dr. José Luis López Sendón

on

  • 2,682 views

Angina crónica estable: La punta del iceberg de la cardiopatía isquémica crónica ...

Angina crónica estable: La punta del iceberg de la cardiopatía isquémica crónica
Congreso de las enfermedades cardiovasculares
Barcelona 22/10/2009
Sociedad Española de Cardiología

Statistics

Views

Total Views
2,682
Views on SlideShare
2,631
Embed Views
51

Actions

Likes
2
Downloads
0
Comments
0

5 Embeds 51

http://www.secardiologia.es 28
http://profesionales.secardiologia.es 16
http://www.slideshare.net 5
http://health.medicbd.com 1
http://www.health.medicbd.com 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Angina crónica estable - Dr. José Luis López Sendón Angina crónica estable - Dr. José Luis López Sendón Presentation Transcript

  • Guias ESC Angina Crónica Estable ¿Son relevantes? José López-Sendón Hospital Universitario La Paz. Madrid. Spain
    • Conflict of interest: Research support from:
    • Servier, BMS, Sanophy-Aventis, Lilly, Bayer, Roche, GKS, Menarini
    • Chronic Stable Angina
    • Chest pain
    • Secondary to myocardial ischemia
    • Not unstable
    • Recent onset
    • Progressive
    • Prolonged
    • Urgent admission to hospital (not really!)
  • Circulation 2003;108:1263. Kern MJ. In: Braunwald’s Heart Disease. 7th ed. 2005. Sigwart U et al. Silent Myocardial Ischemia. New York: Springer-Verlag; 1984: 29 Abnormalities evolving during ischaemia Magnitude of ischaemia Duration of ischaemia (sec) V entricular dysfunction ECG changes ANGINA Metabolic alterations Necrosis Sudden Death
  • Vasospastic Angina Syndrome X Angina due to fixed coronary flow limitation Typical Angina Atypical Angina >70% Coronary Lesion(s) Intermediate Lesion(s) Angiographically Smooth
  •  
  • Angina 20.000 - 40.000 / 1.000.000
  • Knowledge/Science (Clinical trials) Education Marketing
    • Implementation
    • Tools
    • Programs
    • Quality controls
    • Implementation
    • - Surveys
    • Quality controls
    • Impact on outcome
    • - Trials-Euroaction-like
    Guidelines Recommendations Refinement
  • Knowledge/Science (Clinical trials) Education Marketing
    • Implementation
    • Tools
    • Programs
    • Quality controls
    • Implementation
    • - Surveys
    • Quality controls
    • Impact on outcome
    • - Trials-Euroaction-like
    Guidelines Recommendations Refinement
  • Source Value Evidence Clinical experience worthless C Surrogate terrible C Observation registry poor C Case control poor C Small clinical trial well, … B Metaanalysis Good ? B Large clinical trial Good B ≥ 2 clinical trials Appropriate A Guidelines. What evidence ? JP Bassand Circa 2007
  • ¨ C ¨ evidence Impressionist medicine
  • Knowledge/Science (Clinical trials) Education Marketing
    • Implementation
    • Tools
    • Programs
    • Quality controls
    • Implementation
    • - Surveys
    • Quality controls
    • Impact on outcome
    • - Trials-Euroaction-like
    Guidelines Recommendations Refinement
  • AIMS of therapy 1 Immediate pain relief 2 Relief of symptoms, control of ischemia, improve functional class 3 Improve prognosis ESC Stable Angina Guidelines Eur Heart J 2006;27:1341
    • Ischaemic Heart Disease: Therapeutic Options
    • Lifestile: Exercise, Diet, No smoking
    • Medication: Aspirin, Statin, BB, ACE-i, other
    • Revascularization
  •  
  • Contraindications Intolerant / contraindications Aspirin 75-150 mg od Statin ACEI in proven CVD β-blocker in post MI Clopidogrel Lower dose / alternative agent Treatments aimed at Improving Prognosis ESC Guidelines Stable Angina Eur Heart J. 2006; 27:1341
  • Treatments aimed at Symptom Relief Betablockers, 1 st line treatment Contraindication or intolerant Insuficient control of angina / ischaemia Add Other option
  • Treatments aimed at Symptom Relief Betablockers, 1 st line treatment Ca antagonists : Amlodipine: Low heart rate, HT Diltiacem, verapamil: Tach, HT Ivabradine : Heart rate > 70 b/m Nitrate / Nicorandil : General Option Ranolazine : Post ACS (no incluido en guias 2006) Contraindication or intolerant Insuficient control of angina / ischaemia Add Other option
  • Treatments aimed at Symptom Relief Betablockers, 1 st line treatment Contraindication or intolerant Insuficient control of angina / ischaemia Add Other option Consider revascularization if high risk or ischemia Not controlled Ca antagonists: Amlodipine: Low heart rate, HT Diltiacem, verapamil: Tach, HT Ivabradine : Heart rate > 70 b/m Nitrate / Nicorandil : General Option Ranolazine : Post ACS
  • EHS Stable angina BMJ 2006;332:262
  • PCI ESC Stable Angina Guidelines Eur Heart J 2006;27:1341
  • Revascularisation. PCI ESC Stable Angina guidelines 2006 (draft) CABG
  • Survival Free of Death from Any Cause and Myocardial Infarction Number at Risk Medical Therapy 1138 1017 959 834 638 408 192 30 PCI 1149 1013 952 833 637 417 200 35 Years 0 1 2 3 4 5 6 0.0 0.5 0.6 0.7 0.8 0.9 1.0 PCI + OMT Optimal Medical Therapy (OMT) Hazard ratio: 1.05 95% CI (0.87-1.27) P = 0.62 7 NEJM 2007;356:1506
  • Freedom from Angina During Long-Term Follow-up The comparison between the PCI group and the medical-therapy group was significant at 1 year ( P<0.001) and 3 years (P=0.02) but not at baseline or 5 years. NEJM 2007;356:1506 PCI + OMT OMT Angina free – no.
      • Baseline
    12% 13%
      • 1 Yr
    66% 58%
      • 3 Yr
    72% 67%
      • 5 Yr
    74% 72%
  • NEJM 2007;356:1506 Optimal Medical Treatment
  • Optimal Medica therapyl vs Optimal Revascularization BARI 2D N Engl J Med 2009;360:2503-15
  • BARI 2D N Engl J Med 2009;360:2503-15 Optimal Medical Treatment
  • Knowledge/Science (Clinical trials) Education Marketing
    • Implementation
    • Tools
    • Programs
    • Quality controls
    • Implementation
    • - Surveys
    • Quality controls
    • Impact on outcome
    • - Trials-Euroaction-like
    Guidelines Recommendations Refinement
  • Full text www.escardio.org CME programs European National Local
  • What influence your decision in practice most SAPHE study: Internists and geriatricians Internist Geriatrician Cardiologist Guidelines 27% 9 R - 41 NL 32% 9 R - 53 NL Expert opinion 31% 21 UK,S - 47 R 30% 19 S - 40 S Articles 11% 29% Health care authorities 6% 1 -19 F,S 4% (0 - 14 F,S)
  • Knowledge/Science (Clinical trials) Education Marketing
    • Implementation
    • Tools
    • Programs
    • Quality controls
    • Implementation
    • - Surveys
    • Quality controls
    • Impact on outcome
    • - Trials-Euroaction-like
    Guidelines Recommendations Refinement
  • Knowledge/Science (Clinical trials) Education Marketing
    • Implementation
    • Tools
    • Programs
    • Quality controls
    • Implementation
    • - Surveys
    • Quality controls
    • Impact on outcome
    • - Trials-Euroaction-like
    Guidelines Recommendations Refinement Need & Opportunity
  • Knowledge/Science (Clinical trials) Education Marketing
    • Implementation
    • Tools
    • Programs
    • Quality controls
    • Implementation
    • - Surveys
    • Quality controls
    • Impact on outcome
    • - Trials-Euroaction-like
    Guidelines Recommendations Refinement
  •  
  • 0 50 100 ACEI Rx Readmissions Treatment Rates (%) 1-year Mortality Pre-Intervention (n=11,038) Post-Intervention (n=8,045) 18* 23 65 95* 38* 46 Intermountain Health Care: 10 Hospitals Pre- 1/96-12/98 n=11,038 to 1/99-3/00 n=8,045. Pearson. Circulation. 2001;104:II-838. HR 0.80 P <0.0001 HR 0.77 P <0.0001 Institutional heart failure discharge medication program reduces readmissions and mortality
    • Conclusions
    • Guidelines provide evidence based recommendations
    • Following guidelines improve outcomes?
    • New information needed
    • Implementation tools needed
    • Update of guidelines needed
  • Gracias